1. Home
  2. SCLX vs FEMY Comparison

SCLX vs FEMY Comparison

Compare SCLX & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • FEMY
  • Stock Information
  • Founded
  • SCLX 2011
  • FEMY 2004
  • Country
  • SCLX United States
  • FEMY United States
  • Employees
  • SCLX N/A
  • FEMY N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • FEMY Medical/Dental Instruments
  • Sector
  • SCLX Health Care
  • FEMY Health Care
  • Exchange
  • SCLX Nasdaq
  • FEMY Nasdaq
  • Market Cap
  • SCLX 35.7M
  • FEMY 29.9M
  • IPO Year
  • SCLX N/A
  • FEMY 2021
  • Fundamental
  • Price
  • SCLX $13.63
  • FEMY $0.82
  • Analyst Decision
  • SCLX Strong Buy
  • FEMY Strong Buy
  • Analyst Count
  • SCLX 3
  • FEMY 3
  • Target Price
  • SCLX $367.50
  • FEMY $8.67
  • AVG Volume (30 Days)
  • SCLX 225.6K
  • FEMY 151.8K
  • Earning Date
  • SCLX 08-12-2025
  • FEMY 08-07-2025
  • Dividend Yield
  • SCLX N/A
  • FEMY N/A
  • EPS Growth
  • SCLX N/A
  • FEMY N/A
  • EPS
  • SCLX N/A
  • FEMY N/A
  • Revenue
  • SCLX $50,710,000.00
  • FEMY $1,699,232.00
  • Revenue This Year
  • SCLX $68.30
  • FEMY $283.83
  • Revenue Next Year
  • SCLX $124.48
  • FEMY $161.03
  • P/E Ratio
  • SCLX N/A
  • FEMY N/A
  • Revenue Growth
  • SCLX 7.79
  • FEMY 61.97
  • 52 Week Low
  • SCLX $3.60
  • FEMY $0.69
  • 52 Week High
  • SCLX $57.75
  • FEMY $1.80
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 65.59
  • FEMY 36.59
  • Support Level
  • SCLX $10.14
  • FEMY $0.91
  • Resistance Level
  • SCLX $17.76
  • FEMY $0.93
  • Average True Range (ATR)
  • SCLX 1.79
  • FEMY 0.04
  • MACD
  • SCLX 0.52
  • FEMY -0.01
  • Stochastic Oscillator
  • SCLX 57.45
  • FEMY 14.14

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: